Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
+0.22 (1.23%)
Real-time:   10:34AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.78 - 18.19
52 week 3.55 - 18.19
Open 18.12
Vol / Avg. 1.08M/6.43M
Mkt cap 5.31B
P/E     -
Div/yield     -
EPS -0.62
Shares 286.46M
Beta 1.80
Inst. own 77%
Feb 27, 2017
Q4 2016 Exelixis Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 14, 2016
Exelixis Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - 3:40PM EST - Add to calendar
Nov 29, 2016
Exelixis Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 15, 2016
Exelixis Inc at Stifel Healthcare Conference
Nov 3, 2016
Q3 2016 Exelixis Inc Earnings Call - Webcast
Nov 3, 2016
Q3 2016 Exelixis Inc Earnings Release
Oct 10, 2016
Exelixis Inc and Ipsen SA Conference Call to Discuss European Society for Medical Oncology 2016 Congress - Webcast
Sep 13, 2016
Exelixis Inc at Morgan Stanley Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -18.14% -456.63%
Operating margin -10.47% -326.65%
EBITD margin - -320.08%
Return on average assets -8.83% -51.78%
Return on average equity - -
Employees 115 -
CDP Score - -


210 E Grand Ave
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Christopher J. Senner Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. President, Product Development and Medical Affairs and Chief Medical Officer
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Scientific Strategy, Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Jeffrey J Hessekiel Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Deborah Burke Senior Vice President - Finance, Controller
Age: 59
Bio & Compensation  - Reuters
Julie Anne Smith Director
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters